Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: February 18, 2011
Last updated: November 4, 2011
Last verified: November 2011

The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cardiovascular Risk in General Practice in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Enrollment: 9246
Study Start Date: October 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;

Detailed Description:



Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Primary care


Inclusion Criteria:

  • Without any personal history of coronary disease
  • Non treated with lipid-lowering agents
  • Lipid test = 1 year old
  • Presenting at least one cardiovascular risk
  • Visiting their General Practitioner

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its identifier: NCT01308372

  Show 587 Study Locations
Sponsors and Collaborators
Principal Investigator: Eric BRUCKERT, Pr. Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator: Jean DALLONGEVILLE, Dr. Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator: Jean FERRIERES, Pr. CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator: Serge KOWNATOR, Dr. Thionville -Société Française de Cardiologie
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT01308372     History of Changes
Other Study ID Numbers: NIS-CFR-XXX-2011/1
Study First Received: February 18, 2011
Last Updated: November 4, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
cardiovascular risk
General practice
Primary prevention
Non treated patients processed this record on April 16, 2014